EP1858517 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF SCHIZOPHRENIA AND RELATED DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 21.01.2011 Database last updated on 02.09.2024 | Most recent event Tooltip | 21.01.2011 | Application deemed to be withdrawn | published on 23.02.2011 [2011/08] | Applicant(s) | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | For:DE
Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173 55216 Ingelheim / DE | [2007/48] | Inventor(s) | 01 /
PYKE, R. c/oBoehringer Ingelheim Pharmaceuticals,Inc 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877-0368 / US | 02 /
CECI, Angelo Obere Schuegelestrasse 20 88441 Mittelbiberach / DE | [2007/48] | Representative(s) | Hammann, Heinz, et al Boehringer Ingelheim GmbH CD-Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | [N/P] |
Former [2009/48] | Hammann, Heinz, et al Boehringer Ingelheim GmbH CD-Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | ||
Former [2007/48] | Hammann, Heinz, et al Boehringer Ingelheim GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | Application number, filing date | 06736660.9 | 28.02.2006 | [2007/48] | WO2006US07379 | Priority number, date | US20050658566P | 04.03.2005 Original published format: US 658566 P | [2007/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2006096439 | Date: | 14.09.2006 | Language: | EN | [2006/37] | Type: | A2 Application without search report | No.: | EP1858517 | Date: | 28.11.2007 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.09.2006 takes the place of the publication of the European patent application. | [2007/48] | Search report(s) | International search report - published on: | EP | 08.02.2007 | Classification | IPC: | A61K31/496, A61K9/36, A61K9/48, A61P25/18 | [2007/48] | CPC: |
A61K45/06 (EP,US);
A61K31/198 (EP,US);
A61K31/405 (EP,US);
A61K31/445 (EP,US);
A61K31/496 (EP,US);
A61K31/519 (EP,US);
A61K31/5415 (EP,US);
A61K31/551 (EP,US);
A61K31/5513 (EP,US);
A61K9/2009 (EP,US);
A61K9/2018 (EP,US);
A61K9/2054 (EP,US);
A61K9/2059 (EP,US);
A61K9/2866 (EP,US);
A61K9/4858 (EP,US);
A61K9/4866 (EP,US);
A61P25/16 (EP);
A61P25/18 (EP);
A61P25/20 (EP);
A61P25/22 (EP);
A61P25/24 (EP);
| C-Set: |
A61K31/198, A61K2300/00 (US,EP);
A61K31/405, A61K2300/00 (US,EP);
A61K31/445, A61K2300/00 (US,EP);
A61K31/496, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US);
A61K31/5415, A61K2300/00 (EP,US); | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/48] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | YU | Not yet paid | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG UND/ODER VERHINDERUNG VON SCHIZOPHRENIE ODER VERWANDTEN KRANKHEITEN | [2007/48] | English: | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF SCHIZOPHRENIA AND RELATED DISEASES | [2007/48] | French: | COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT ET/OU A LA PREVENTION DE LA SCHIZOPHRENIE ET DE MALADIES ASSOCIEES | [2007/48] | Entry into regional phase | 04.10.2007 | National basic fee paid | 04.10.2007 | Designation fee(s) paid | 04.10.2007 | Examination fee paid | Examination procedure | 04.10.2007 | Examination requested [2007/48] | 20.12.2007 | Despatch of a communication from the examining division (Time limit: M06) | 19.06.2008 | Reply to a communication from the examining division | 01.09.2010 | Application deemed to be withdrawn, date of legal effect [2011/08] | 07.09.2010 | Despatch of a communication from the examining division (Time limit: M04) | 07.10.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2011/08] | Fees paid | Renewal fee | 29.02.2008 | Renewal fee patent year 03 | 02.03.2009 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 28.02.2010 | 05   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP1256343 (BECK JUERGEN K DR [DE]) [Y] 1-17* paragraphs [0008] , [0038]; example - *; | [X]WO03013539 (BOEHRINGER INGELHEIM PHARMA [DE], et al) [X] 1-17 * page 2, paragraph L; example - *; | [X]US2003060475 (BORSINI FRANCO [DE]) [X] 1-17 * paragraph [0009] *; | [Y]WO03097058 (BOEHRINGER INGELHEIM PHARMA [DE], et al) [Y] 1-17 * example - *; | [Y]US2004147581 (TAYLOR DUNCAN P [US], et al) [Y] 1-17 * Compound H12; paragraph [0030]; table 3 *; | [PX]WO2005102342 (BOEHRINGER INGELHEIM INT [DE], et al) [PX] 1-17 * claim 2 *; | [X] - BORSINI F ET AL, "LACK OF INTERACTION BETWEEN FLIBANSERIN AND ANTIDEPRESSANTS IN INDUCING SEROTONERGIC SYNDROME IN RATS", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, (2001), vol. 4, no. 1, ISSN 1461-1457, pages 9 - 15, XP009069271 [X] 1-17 * page 13 * DOI: http://dx.doi.org/10.1017/S1461145701002206 | [Y] - BORSINI F. ET AL., "Mechanism of action of flibanserin in the learned helplessness paradigm in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, (2001), vol. 433, pages 81 - 89, XP002400868 [Y] 1-17 * figure 5 * DOI: http://dx.doi.org/10.1016/S0014-2999(01)01495-9 |